DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Cocco E, Carmona FJ, Razavi P. et al.
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Sci Signal 2019;
DOI: 10.1126/scisignal.aa9773.
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.